Paige Launches AI Software to Enable Accurate and Efficient Detection of Breast Cancer Lymph Node Metastases


NEW YORK–(BUSINESS WIRE)–Paige, the global leader in pathology AI-based diagnostic software, today launched its latest product, Paige Breast Lymph Node, an AI medical device software that helps pathologists detect whether breast cancer has metastasized to lymph nodes, alongside pathologists’ interpretive examination*. The product was unveiled at the annual meeting of the American and Canadian Academy of Pathology (USCAP) which took place March 19-24, 2022.

Determining whether breast cancer has spread to the lymphatic system is critical to a patient’s diagnosis and planned treatment. Due to the large area of ​​tissue and the size of small micro-metastases, a pathologist’s accurate assessment of a lymph node slide can be tedious and time-consuming.

Designed to increase the accuracy and efficiency of detecting breast cancer metastases most likely to be missed, Paige Breast Lymph Node leverages AI to enable pathologists to identify tumor metastases of any size, including small micrometastases, more efficiently and reliably. It is designed to improve diagnostic accuracy for the most subtle metastatic foci and has over 98% sensitivity at the slide to detect metastases of any size. A positive indication of metastatic breast cancer will be displayed at the level of individual lymph nodes with Paige’s proprietary TissueMap, which highlights all regions on a slide that are suspicious for cancer. In addition, slides and suspected cases of positive lymph nodes are highlighted, facilitating their prioritization and efficient review by the pathologist.

Advertising statistics

Hours displayed: 24994
Number of visits: 234

“Accurate detection of breast cancer metastases is paramount for physicians and their patients, but it can be a laborious manual task for pathologists,” said David Klimstra, MD, founder and chief medical officer of Paige. “Paige Breast Lymph Node offers pathologists a faster, more efficient way to analyze large amounts of lymph node tissue, as well as peace of mind for them and their patients.”

Paige Breast Lymph Node will be available immediately as part of the Paige Breast Suite. This software uses the same underlying AI technology as Paige Prostate, which can work with a wide range of data, staining techniques, and scanning artifacts, resulting in generalizable AI that can be quickly deployed in a variety of laboratories and hospitals.

“Paige Breast Lymph Node reinforces the value of the Paige Breast Suite for clinical pathologists,” said Andy Moye, Ph.D., Chief Executive Officer of Paige. “This product launch is an important step in our overall go-to-market strategy as we bring the power of our AI platform to new disease areas. Along with our FDA-approved Paige Prostate, the generalizability of AI further validates the broader use of Paige’s software to help the pathologist diagnose cancer.

Paige will host a webinar on March 30 to demonstrate how Paige’s Breast Lymph Node can be used in clinical practice.

About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, MD, and colleagues at Memorial Sloan Kettering Cancer Center (MSK). The company develops computational pathology products designed to enable patients and their care teams to make effective and more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige has created a platform to deliver this new technology to pathologists to transform their workflow and increase confidence and productivity. of the diagnosis. Paige’s products provide information to pathologists and oncologists so they can efficiently arrive at more accurate diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product.

Previous On-Demand Webinar: Lateral Hires - Issues to Consider
Next Animal Tracking Software Market Size and Analysis by 2022-2029 – Zebtrack, ViewPoint, ToxTrac, Simon Garnier, Noldus Information Technology, Movebank, EthoVision XT